From here, 14 COVID-19 vaccines are coming to the clinic

2022-09-10 0 By

At present, more than 1.2 billion people in China have been vaccinated with COVID-19 vaccines, building a strong immune barrier for the country’s epidemic prevention and control and protecting people’s lives.However, few people know that in the human struggle against disease, animal model is the first step to understand the disease, is one of the “touchstones” to conquer the disease, with animal model, we can scientifically understand the disease, find drug targets, test drugs or vaccines.At the beginning of the New Year, the reporter visited the Research team at the Institute of Laboratory Animals of the Chinese Academy of Medical Sciences (IAMR), which developed the world’s first ANIMAL model of COVID-19 and successfully created a “touchstone” for COVID-19 vaccine in China.”So far, we have completed the evaluation of more than 50 COVID-19 vaccines and 130 COVID-19 drugs deployed by the country, and 14 vaccines, including inactivated vaccines produced by Sinovac and Sinopharmics, have entered the clinic.”The Institute of Laboratory Animals of the Chinese Academy of Medical Sciences, located in Panjiayuan, Beijing, is a Chinese building.Here, the reporter saw the captain of this team – Professor Qin Chuan.She wore her naturally curly hair in braids over her shoulders and wore a grey velvet suit.”Most of the announced domestic adenovirus vaccines, inactivated vaccines and recombinant novel coronavirus vaccines, as well as many foreign vaccines, have been tested on animals in the INSTITUTE,” she said.Sitting opposite the reporter, Qin recalled that “fast” and “accurate” were the beliefs she and all her team members shared at that time.”The sooner animal models are established, the sooner vaccines and drugs are available.”Flashback to the beginning of the COVID-19 outbreak.At that time, the state listed animal models as one of its five major areas of focus.Qin chuan clearly remembers that on December 31, 2019, she and her team were commissioned to undertake a series of scientific and technological projects, including “COVID-19 animal model construction”.”In just seven days, from the acquisition of the virus on 23 January 2020 to 29 January 2020, we successfully established a transgenic mouse model of humanized novel Coronavirus receptor.”Qinchuan said.Each node of this thrilling scientific journey is measured by “days” — on February 14, 2020, they established the world’s first COVID-19 experimental monkey model just nine days after receiving a high dose of virus.So far, they have succeeded in creating a “litmus test” for COVID-19 vaccines and medicines.At this point, experts from other countries are still at the stage of discussing ideas and solutions.In the seminar held by the World Health Organization, when the team of THE Institute of Animal Research showed the animal model developed in China, and introduced the experience and methods in detail, some foreign experts immediately exclaimed: “unbelievable.”As a result, the COVID-19 animal model developed by the IRI team has been adopted internationally as a common method for animal model development of COVID-19, as well as a common standard for vaccine and drug evaluation.Since then, using accurate animal models, the IRI team has confirmed the causative agent of COVID-19 and confirmed that the virus invades host receptors, revealing the infection, pathogenic characteristics and route of transmission.In the view of Researcher Jiangning Liu, deputy Director of iRI, the novel Coronavirus animal model is in a tight time frame.The reason why the IMRI team has been able to develop novel Coronavirus animal models so quickly lies in the 17 years of emergency animal model research.Seventeen years ago, Qin led his team to create the first animal model of SARS.Over the past 17 years, our team has worked tirelessly to develop animal models for avian influenza, hand, foot and mouth disease, H1N1, H7N9, Zika and other domestic and international epidemics, effectively promoting clinical treatment and epidemic control.It is the long-term accumulation of scientific research and talents that enables the team to quickly “fight back” against COVID-19, build a bridge between laboratory and clinic, and make the research and development of COVID-19 vaccine and drug into the clinical barrier.At the beginning of the New Year, the clock points to the third year of COVID-19 technology, and the team is still busy.Can COVID-19 vaccine protect against Omicron?This is research being carried out by the Institute of Animal Research.The campaign lasted for two years, and the RRI team never took off its “battle robes”.Recently, they successfully isolated the omicron mutant strain for the first time in China and are studying to assess the resistance of Chinese people to omicron after vaccination.”Our animal model team has been given a very difficult task by the state to answer a series of questions using animal models.”Liu Jiangning said.”Can existing vaccines work against the mutant strain?How long does the vaccine last?Can bivalent or polyvalent vaccines protect against mutants?What is the safety and efficacy of sequential vaccination of vaccine products with different technologies?Can a vaccine successfully block transmission be developed?What is the pathogenesis of critical illness?Can we screen and stockpile effective drugs for critically ill patients?It is these questions that people are most concerned about that the research team is fighting another “hard battle”.As one of the laboratories with the highest risk level in China, the biosafety level iii laboratory of THE Institute is in the rear of the battle against the epidemic, but it is also covered with smoke.”It is extremely dangerous for laboratory staff to have frequent contact with the virus, infected animals, handling excreta, taking chest films and dissecting animals.”Qinchuan compares it to the most dangerous battlefield.Here, the researchers were exposed to highly concentrated virus, and the infected animals were emotionally unstable and easily infected by scratching and biting them.Because of this, the families of the team members all have one thing in common.”They don’t care what your salary is, whether you are tired or not. The only thing they worry about most is safety. Some family members even collapse when they are a few minutes late to answer the phone.”Liu Jiangning said.To ease these worries, qin Chuan, Liu Jiangning and fellow researchers Deng Wei, Bao Linlin and Xu Yanfeng guide young people to pass on their experience and skills every time there is a new experimental operation.”We will shoulder the historical responsibility to promote more medical breakthroughs from ‘0 to 1’ and contribute to the development of people’s drug safety, national biosafety and independent biomedical industry.””From the older generation of scientists such as Lin Qiaozhi, Gu Fangzhou and Ba Denian to our generation of medical scientists, the needs of the country are our beliefs,” Qin said.After years of accumulation, with the efforts of the whole team, IRI has established the largest animal resource pool of genetic diversity in the world and the largest animal model pool of human diseases in China, with more than 1/3 of the world’s animal resources of genetic diversity, which will provide a solid guarantee for the independent research and development of animal models in China.(Our reporter Zhan Yuan, our correspondent Jiang Cheng)